Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASIM-POST Ph+
NCT07493408Phase 2Not yet recruiting
- Sponsor
- The University of Hong Kong
- Start
- Mar 2026
- Primary completion
- Dec 2035
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of asciminib in acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), sponsored by The University of Hong Kong. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
asciminib
03
Conditions
acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT07493408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493408.